House dust allergy and immunotherapy

Abstract

HDM allergy is associated with asthma, allergic rhinitis and atopic dermatitis. In many countries childhood asthma is predominantly found in HDM-allergic children with their probability of developing disease being proportional to their IgE antibody titers and the early development of Th2 responses. While the pathogenesis is complex and increasingly linked to infection the immunologically-based allergen immunotherapy and anti-IgE antibody therapy are highly beneficial. Immunotherapy could be a short-term treatment providing lifelong relief but the current regimens depend on repeated administration of allergen over years. Immunological investigations point to a contribution of responses outside the Th2 pathway and multiple potential but unproven control mechanisms. Over half of the IgE antibodies are directed to the group 1 and 2 allergens with most of remainder to the group 4, 5, 7 and 21 allergens. This hierarchy found in high and low responders provides a platform for introducing defined allergens into immunotherapy and defined reagents for investigation.

Keywords: :

• Dermatophagoides
• Blomia
• allergen
• IgE
• IgG
• T-cell
• immunotherapy
• cytokine
• asthma
• house dust mite

Disclosure of Potential Conflicts of Interest

Wayne Thomas is an inventor on patents for house dust mite allergens assigned to the Telethon Institute for Child Health

Acknowledgment

Wayne Thomas is a fellow of the National Health and Medical Research Council of Australia.